In another study, the combination of statins (atorvastatin or simvastatin) with EGFR-TKIs (erlotinib or gefitinib) prolonged PFS in NSCLC harboring KRAS mutations [22]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.